Coupling optical and potentiometric measurements with magnetic levitation

WO2024196902A3PCT designated stage expired Publication Date: 2024-11-14WHITESIDES GEORGE M +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/020475
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-17
Filing Date
2024-03-18
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for optical and potentiometric measurements require large sample volumes, are often destructive, and can only measure one type of property at a time, making them inefficient and costly, especially when analyzing enzyme kinetics like butyrylcholinesterase activity.

Method used

A magnetic levitation system integrated with optical and potentiometric sensors allows for simultaneous, non-destructive measurement of multiple properties of a small sample volume, including concentration, reaction kinetics, and structural behavior, using a combination of light transmittance and electrochemical potential sensors.

Benefits of technology

This approach enables high-accuracy, high-precision, cost-effective, and time-resolved detection of chemical and biological species, facilitating the analysis of enzyme kinetics and potentially advancing personalized anesthesiology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024020475_14112024_PF_FP_ABST
    Figure US2024020475_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein is a system comprising a first magnet and a second magnet. A vessel that is configured to receive a first phase and a second phase is held between the first magnet and the second magnet. The first magnet and the second magnet are configured to levitate the first phase within the vessel. The system includes a light source configured to transmit optical radiation through the first phase. The system includes a first sensor configured to measure transmittance of optical radiation from or through the first phase. The system includes a second sensor configured to measure electrochemical potential in the second phase.
Need to check novelty before this filing date? Find Prior Art

Description

COUPLING OPTICAL AND POTENTIOMETRIC MEASUREMENTS WITHMAGNETIC LEVITATIONCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to co-pending United States Provisional Application Serial No. 63 / 490,933, filed March 17, 2023, the contents of which are incorporated by reference.COPYRIGHT NOTICE

[0002] This patent disclosure may contain material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.FIELD OF THE INVENTION

[0003] The present disclosure relates to methods of characterizing chemical processes or biological processes using a magnetic levitation system. In particular, the present disclosure relates to optical and potentiometric characterization of enzyme activity using a magnetic levitation system.BACKGROUND

[0004] Magnetic levitation (MagLev) suspends objects against the force of gravity using magnetic fields and field gradients. A MagLev system is classified as a magnetic suspension (MS) system. The MagLev structure consists of two magnets that attract a paramagnetic medium in opposite directions. A MS system uses magnetic forces in order to counteract gravity. In a MS system, suspensions of chemicals or objects can be separated based on density, inside of a vial containing a paramagnetic medium.

[0005] Historically, MagLev systems have been mainly used to determine the density of an object, since it dictates the levitation height of the droplet in the cuvette. In biology, MagLev has been applied to determine biophysical qualities of proteins (1), including the quantification of a protein’s density under an applied magnetic field using a symmetrical magnetic setup (2). A MagLev system can also be utilized to perform touchless chemical reactions in a controlled environment t3Y

[0006] Butyrylcholinesterase is an enzyme belonging to the class of serine hydrolases (4, 5). Being aware of an individual’s BChE concentration and activity in blood is fundamental as it is responsible for the hydroxylation of many commonly used drugs, such as succinylcholine (SuCh) (6).

[0007] Magnetic levitation offers the chance for touchless measurements of chemical reactions, but its capability in biological measurements is not frequently explored. While work has been done adapting biological specimens to magnetic levitation systems, the experiments focus on density measurements rather than measurements of biological enzymatic reaction. Despite an application of MagLev in enzyme kinetics being recorded in literature, no data has been presented regarding the optimal condition that it offers for an optical analysis of a suspended sample. A MagLev system capable of measuring enzyme kinetics has the potential to progress the field of personalized anesthesiology (7). Coupling optical and potentiometric measurements with Maglev enables high accuracy, high precision, cost effective, and time- resolved detection of chemical and biological species, their concentration, reaction kinetics, activity, formulation, structural behavior, and properties.

[0008] The present disclosure discloses a magnetic levitation system with one or more sensors integrated with the system. In certain embodiments, the sensors integrated with the system allow for the simultaneous measurement of multiple properties of a magnetically levitated sample. In certain embodiments, the properties measured include: concentration, reaction kinetics, activity, formulation, structural behavior, optical properties, potentiometric properties, and other chemical, physical, and biological properties. In certain embodiments, the system also integrates a light source. In certain embodiments, the system integrates a first sensor configured to measure a transmittance of an optical radiation, a second sensor configured to measure an electrochemical potential, and a light source configured to transmit an optical radiation. In certain embodiments, the first sensor, the second sensor, and the light source are concurrently used to measure different properties of a sample. In certain embodiments, the system provides simultaneous measurements of different properties of a sample. In certain embodiments, the system provides simultaneous measurements of optical and potentiometric properties of a magnetically levitated sample. In certain embodiments, the system is a table-top system that integrates inexpensive, readily obtainable components (e.g. magnets, light source, sensors).

[0009] The present disclosure discloses a method for simultaneously measuring multipleproperties of a single sample that is levitated between two magnets. In certain embodiments, magnetic levitation concentrates the sample to a droplet or multiple droplets. In certain embodiments, the method allows simultaneous optical and potentiometric measurements of a single sample that is levitated between two magnets.

[0010] Contemporary instruments and methods for potentiometric and optical measurements may require large volumes or masses of a sample to be analysed. In many cases, contemporary instruments only allow one type of measurement of a sample at a time (e.g., optical measurements, or potentiometric measurements). In some cases, the methods may be destructive to the sample. In some cases, the sample may be expensive to prepare. In some cases, the method of analysis may require significant amounts of time to measure the properties of the sample. In some cases, the method may require hours to prepare the sample and measure the properties of the sample.

[0011] There is a need for cost-effective systems and efficient methods for conducting optical and potentiometric measurements for probing a sample’s concentration, reaction kinetics, activity, formulation, structural behavior, optical properties, potentiometric properties, and other chemical, physical, and biological properties. Further, there is a need for systems and methods which provide simultaneous, non-destructive measurements of a small volume or mass of a sample.SUMMARY

[0012] Certain embodiments of the present disclosure describe a system including a first magnet and a second magnet, a vessel held between the first magnet and the second magnet, a light source, a first sensor and a second sensor; wherein the vessel is configured to receive a first phase and a second phase, the first magnet and the second magnet are configured to levitate the first phase, the light source is configured to transmit an optical radiation through the first phase, the first sensor is configured to measure a transmittance of an optical radiation from or through the first phase, and the second sensor is configured to measure an electrochemical potential in the second phase.

[0013] In certain embodiments, the north pole of the first magnet faces the north pole of the second magnet.

[0014] In certain embodiments, the south pole of the first magnet faces the south pole of the second magnet.

[0015] In certain embodiments, the first magnet and the second magnet each independently include a permanent magnet or an electromagnet.

[0016] In certain embodiments, the first magnet and the second magnet each independently include a permanent magnet.

[0017] In certain embodiments, the first magnet and the second magnet each independently include one or more of Nd, NdFeB, SmCo, ceramic, or AlNiCo.

[0018] In certain embodiments, the first magnet and the second magnet each independently include NdFeB.

[0019] In certain embodiments, the vessel is one of transparent, semi-transparent, or translucent.

[0020] In certain embodiments, the vessel is transparent.

[0021] In certain embodiments, the vessel includes flat sides.

[0022] In certain embodiments, the vessel is a squared-section cuvette.

[0023] In certain embodiments, the vessel material includes one or more of glass, plastic, quartz, polycarbonate, polymethylmethacrylate.

[0024] In certain embodiments, the first phase and the second phase are immiscible.

[0025] In certain embodiments, the first phase and the second phase are partially miscible.

[0026] In certain embodiments, at the interface between the first phase and the second phase, a transfer of one or more of an ion, a molecule, an amphiphile, a chemical reagent, a biomolecule, or a macromolecule occurs from the first phase to the second phase or the second phase to the first phase.

[0027] In certain embodiments, the first phase includes one or more of a liquid, a solid, a solution, a suspension, an emulsion, a colloid, a microemulsion, a liquid crystal, or a gel.

[0028] In certain embodiments, the first phase includes one or more of a liquid, a solution, an emulsion, or a colloid.

[0029] In certain embodiments, the first phase includes an emulsion.

[0030] In certain embodiments, the emulsion includes a first aqueous solution and an organic solvent, wherein the first aqueous solution includes an amphiphile.

[0031] In certain embodiments, the amphiphile includes myristoylcholine.

[0032] In certain embodiments, the organic solvent includes one or more of nitrophenyl octyl ether, hexane, hexanol, heptane, heptanol, octane, octanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, or another water-immiscible solvent.

[0033] In certain embodiments, the organic solvent includes nitrophenyl octyl ether.

[0034] In certain embodiments, the first phase is turbid, or transparent, transitions from being turbid to being transparent, or transitions from being transparent to being turbid.

[0035] In certain embodiments, the second phase includes a paramagnetic medium.

[0036] In certain embodiments, the paramagnetic medium includes a second aqueous solution, wherein the second aqueous solution includes paramagnetic salts; or an aqueous- organic hybrid solution of paramagnetic salts.

[0037] In certain embodiments, second aqueous solution includes one or more of MnCl2, MnBr2, FeCh, FeCh, CoBr2, GdCh, Gd2(SO4)3, Er2(SO4)3, and CuSO4.

[0038] In certain embodiments, the aqueous-organic hybrid solution includes one or more of a water-methanol mixture, a water-ethanol mixture, a water-propanol mixture, a water- acetonitrile mixture, a water-dimethyl sulfoxide mixture.

[0039] In certain embodiments, the second aqueous solution includes MnCh.

[0040] In certain embodiments, the second aqueous solution includes a substrate and an enzyme.

[0041] In certain embodiments, the substrate includes a choline derivative, and the enzyme includes butyrylcholine esterase.

[0042] In certain embodiments, the substrate includes one or more of succinyl choline or myristoylcholine.

[0043] In certain embodiments, the substrate includes myristoylcholine.

[0044] In certain embodiments, the second aqueous solution includes human serum.

[0045] In certain embodiments, the light source transmits one or more of ultraviolet, visible, infrared radiation.

[0046] In certain embodiments, the light source transmits visible radiation at a wavelength of 660 nm.

[0047] In certain embodiments, the light source includes a laser, a lamp, a light emitting diode, or a combination thereof.

[0048] In certain embodiments, the light source includes a laser pointer.

[0049] In certain embodiments, the first sensor includes a light sensor.

[0050] In certain embodiments, the first sensor includes a photodetector.

[0051] In certain embodiments, the photodetector includes a photodetector for a ultraviolet-visible spectrophotometer.

[0052] In certain embodiments, the first sensor is aligned with the first phase.

[0053] In certain embodiments, the first sensor is configured to measure one or more of light emitted from the first phase, or light transmitted through the first phase.

[0054] In certain embodiments, the first sensor includes a photodetector for an ultraviolet- visible spectrophotometer; the photodetector being aligned with the first phase; and the photodetector being configured to measure light transmitted through the first phase.

[0055] In certain embodiments, the second sensor includes one or more ion-selective electrodes.

[0056] In certain embodiments, the ion selective electrode is selective for ions in the second phase.

[0057] In certain embodiments, the ion selective electrode is selective for succinylcholine ions or myristoylcholine ions.

[0058] In certain embodiments, the second sensor is an ion-selective electrode configured to measure an electrochemical potential in the second phase based on a concentration of the myristoylcholine ions in the second phase.

[0059] In certain embodiments, the system includes an optical filter.

[0060] In certain embodiments, the optical filter includes a neutral density filter positioned between the light source and the vessel.

[0061] In certain embodiments, the system includes a first magnet and a second magnet, a vessel held between the first magnet and the second magnet, the vessel configured to receive a first phase and a second phase, the first magnet and the second magnet configured to levitate the first phase; a light source, the light source configured to transmit an optical radiation through the first phase; a first sensor, the first sensor configured to measure a transmittance of an optical radiation from or through the first phase; and a second sensor, the second sensor configured to measure an electrochemical potential in contact with the second phase. In certain embodiments, the first magnet and the second magnet include NdFeB; the vessel is a transparent, squared-section cuvette, and the vessel material includes quartz; the first phase is an emulsion including nitrophenyl octyl ether and a first aqueous solution that includes an amphiphile, and the amphiphile includes myristoylcholine; the second phase is a paramagnetic medium including a second aqueous solution that includes MnCh, and one of butyrylcholinesterase or human serum; the light source includes a laser pointer configured to transmit 660 nm optical radiation through the first phase; the first sensor includes a photodetector for an ultraviolet-visible spectrophotometer configured to measure light transmitted from the light source through the first phase; the second sensor includes an ion- selective electrode configured to measure an electrochemical potential in the second phase on the basis of the concentration of myristoylcholine ions in the second phase; and the system includes a neutral density filter positioned between the light source and the vessel.

[0062] Certain embodiments of the present disclosure describe a method including: providing a first phase and a second phase either separately or together to a vessel; disposing the vessel between a first magnet and a second magnet, the disposal of the vessel between the first magnet and the second magnet causing the first phase to levitate; transmitting an opticalradiation through the first phase using a light source; measuring a transmittance of optical radiation from or through the first phase using a first sensor; and measuring an electrochemical potential in the second phase using a second sensor.

[0063] In certain embodiments, the second phase is provided to the vessel before or after providing the first phase to the vessel.

[0064] In certain embodiments, the vessel is disposed between the first magnet and the second magnet before or after providing the first phase to the vessel.

[0065] In certain embodiments, the second phase is provided to the vessel, the vessel is disposed between the first magnet and the second magnet, and then the first phase is provided to the vessel.

[0066] In certain embodiments, the method includes providing one or more additional compounds, reagents, or mixtures to either one of or both of the first phase and the second phase.

[0067] In certain embodiments, the method includes providing a mixture of water and either one of butyrylcholine esterase, or human serum to the second phase.

[0068] In certain embodiments, the north pole of the first magnet faces the north pole of the second magnet.

[0069] In certain embodiments, the south pole of the first magnet faces the south pole of the second magnet.

[0070] In certain embodiments, the first magnet and the second magnet each independently include a permanent magnet or an electromagnet.

[0071] In certain embodiments, the first magnet and the second magnet each independently include a permanent magnet.

[0072] In certain embodiments, the first magnet and the second magnet each independently include one or more of Nd, NdFeB, SmCo, ceramic, or AlNiCo.

[0073] In certain embodiments, the first magnet and the second magnet each independently include NdFeB.

[0074] In certain embodiments, the vessel is one of transparent, semi-transparent, or translucent.

[0075] In certain embodiments, the vessel is transparent.

[0076] In certain embodiments, the vessel includes flat sides.

[0077] In certain embodiments, the vessel is a squared-section cuvette.

[0078] In certain embodiments, the vessel material includes one or more of glass, plastic, quartz, polycarbonate, polymethylmethacrylate.

[0079] In certain embodiments, the first phase and the second phase are immiscible.

[0080] In certain embodiments, the first phase and the second phase are partially miscible.

[0081] In certain embodiments, at the interface between the first phase and the second phase, a transfer of one or more of an ion, a molecule, an amphiphile, a chemical reagent, a biomolecule, or a macromolecule occurs from the first phase to the second phase or the second phase to the first phase.

[0082] In certain embodiments, the first phase includes a liquid, a solid, a solution, a suspension, an emulsion, a colloid, a microemulsion, a liquid crystal, or a gel, or a combination thereof.

[0083] In certain embodiments, the first phase includes a liquid, a solution, an emulsion, a colloid, or a combination thereof.

[0084] In certain embodiments, the first phase includes an emulsion.

[0085] In certain embodiments, the emulsion includes a first aqueous solution and an organic solvent, wherein the first aqueous solution includes an amphiphile.

[0086] In certain embodiments, the amphiphile is myristoylcholine.

[0087] In certain embodiments, the organic solvent includes one or more of nitrophenyl octyl ether, hexane, hexanol, heptane, heptanol, octane, octanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, or another water-immiscible solvent.

[0088] In certain embodiments, the organic solvent includes nitrophenyl octyl ether.

[0089] In certain embodiments, the first phase is turbid, or transparent, transitions from being turbid to being transparent, or transitions from being transparent to being turbid.

[0090] In certain embodiments, the second phase includes a paramagnetic medium.

[0091] In certain embodiments, the paramagnetic medium includes a second aqueous solution, wherein the second aqueous solution includes paramagnetic salts; or an aqueous- organic hybrid solution of paramagnetic salts.

[0092] In certain embodiments, the paramagnetic salt includes one or more of MnCh, MnBr2, FeCh, FeCh, CoBr2, GdCh, Gd2(SO4)3, Er2(SO4)3, and CuSO4.

[0093] In certain embodiments, the aqueous-organic hybrid solution includes one or more of a water-methanol mixture, a water-ethanol mixture, a water-propanol mixture, a water- acetonitrile mixture, or a water-dimethylsulfoxide.

[0094] In certain embodiments, the second aqueous solution includes MnCh.

[0095] In certain embodiments, the second aqueous solution includes a substrate and an enzyme.

[0096] In certain embodiments, the substrate includes a choline derivative, and the enzyme includes butyrylcholine esterase.

[0097] In certain embodiments, the substrate includes one or more of succinyl choline or myristoylcholine.

[0098] In certain embodiments, the substrate includes myristoylcholine.

[0099] In certain embodiments, the second aqueous solution includes human serum.

[0100] In certain embodiments, the light source transmits one or more of ultraviolet, visible, or infrared radiation.

[0101] In certain embodiments, the light source transmits visible radiation at a wavelength of 660 nm.

[0102] In certain embodiments, the light source includes one or more of a laser, a lamp, a light emitting diode.

[0103] In certain embodiments, the light source includes a laser pointer.

[0104] In certain embodiments, the first sensor includes a light sensor.

[0105] In certain embodiments, the first sensor includes a photodetector.

[0106] In certain embodiments, the photodetector includes a photodetector for an ultraviolet-visible spectrophotometer.

[0107] In certain embodiments, the first sensor is aligned with the first phase.

[0108] In certain embodiments, the first sensor is configured to measure light emitted from the first phase, light transmitted through the first phase, or a combination thereof.

[0109] In certain embodiments, the first sensor includes a photodetector for an ultraviolet- visible spectrophotometer; the photodetector being aligned with the first phase; and the photodetector being configured to measure light transmitted through the first phase.

[0110] In certain embodiments, the second sensor includes one or more ion-selective electrodes.[OHl] In certain embodiments, the ion selective electrode is selective for ions in the second phase.

[0112] In certain embodiments, the ion selective electrode is selective for succinylcholine ions or myristoylcholine ions.

[0113] In certain embodiments, the second sensor is an ion-selective electrode configured to measure an electrochemical potential in the second phase based on a concentration of myristoylcholine ions in the second phase.

[0114] In certain embodiments, the method further includes providing an optical filter.

[0115] In certain embodiments, the optical filter includes a neutral density filter.

[0116] In certain embodiments, the neutral density filter is positioned between the light source and the vessel.

[0117] In certain embodiments, the method includes: providing a first phase and a second phase to a vessel; disposing the vessel between a first magnet and a second magnet, the disposal of the vessel between the first magnet and the second magnet causing the first phase to levitate; transmitting an optical radiation through the first phase using a light source; measuring a transmittance of optical radiation from or through the first phase using a first sensor; and measuring an electrochemical potential in the second phase using a second sensor. In certain embodiments, the first magnet and the second magnet include NdFeB; the vessel is a transparent, squared-section cuvette, and the vessel material includes quartz; the first phase is an emulsion including nitrophenyl octyl ether and a first aqueous solution, the first aqueous solution including an amphiphile, and the amphiphile includes myristoylcholine; the second phase is a paramagnetic medium including a second aqueous solution that includes MnCh, and optionally one or more of butyrylcholinesterase or human serum; the second phase is provided to the vessel, the vessel is disposed between the first magnet and the second magnet, the first phase is provided to the vessel, and a mixture of water and one or more of butyrylcholinesterase or human serum is provided to the second phase; the light source includes a laser pointer configured to transmit 660 nm optical radiation through the first phase; the first sensor includes a photodetector for an ultraviolet-visible spectrophotometer configured to measure light transmitted from the light source through the first phase; the second sensor includes an ion- selective electrode configured to measure an electrochemical potential in the second phase on the basis of the concentration of myristate ions in the second phase; and a neutral density filter is positioned between the light source and the vessel.BRIEF DESCRIPTION OF THE DRAWINGS

[0118] FIGS. 1A-1B show the chemical structure drawings of succinylcholine (SuCh) and myristoylcholine (MCh). FIG. 1A shows the structure of SuCh. FIG. IB shows the structure of MCh, presenting the polar tertiary amine head and the 14-carbon alkyl chain.

[0119] FIGS. 2A-2C illustrate the optical-potentiometric-magnetic levitation (0PM) system. FIG. 2A provides an exemplary illustration of the 0PM system and its components. FIG. 2B provides an exemplary schematic of the 0PM system. FIG. 2C is an image of theOPM system and its components.

[0120] FIGS. 3A-3B provides exemplary illustrations of the OPM system. FIG. 3A provides an exemplary illustration of a top-down view of the OPM system and its components. FIG. 3B provides an exemplary illustration of a side-on view of the OPM system and its components.

[0121] FIG. 4 provides an exemplary illustration of a magnetic levitation apparatus used to levitate droplets of 2-Nitrophenyl octyl ether (NPOE), as a model compound to form an oillike phase .

[0122] FIG. 5 provides an exemplary illustration of a neutral density filter which is a filter that reduces the intensity of all wavelengths, or colors, of light beams being shone through it.

[0123] FIG. 6 provides an exemplary illustration of an ion-selective electrode (ISE) which is a sensor that converts the change in the concentration of a specific ion, dissolved in solution, into an electrical potential.

[0124] FIG. 7 provides an exemplary illustration of a laser pointer as a light source of the laser beam.

[0125] FIG. 8 provides an exemplary illustration of a photodetector for a UV-VIS spectrophotometer.

[0126] FIG. 9 provides an exemplary plot of the transmittance spectrum across different light wavelengths for different-sized emulsion droplets.

[0127] FIGS. 10A-10C provide exemplary illustrations of the hydrolysis of myristoylcholine (MCh) to myristic acid / myri state ion and choline, catalyzed by butyrylcholinesterase (BChE). FIG. 10A provides an illustration of the MCh hydrolysis reaction catalyzed by BChE. FIG. 10B shows images of the MCh-BChE active emulsion droplet at 0 s, 20 s, 40 s, and 1000s. FIG. 10C shows an exemplary plot of the decreasing concentration of MCh ions over time as MCh is hydrolyzed by BChE.

[0128] FIG. 11 provides exemplary plots of light intensity registered by the OPM platform measures progress of MC-BChE enzymatic reaction.

[0129] FIG. 12 provides exemplary plots of light intensity over time, measured throughdroplets with different concentrations of human serum, as measured by the OPM system.

[0130] FIG. 13 Provides exemplary plots of the decrease in MCh concentration over time as a result of BChE catalyzed hydrolysis. MCh concentration was probed by an ionic selective electrode (indicated by the electrochemical potential measured). Three different amounts (0.065mL, 0.08mL and O. lmL) of BChE stock solution (50U / mL) were added to the aqueous phase, resulting in different rates of hydrolysis, indicated by the shape of the curves.

[0131] FIG. 14 Provides an exemplary plot of an ISE calibration curve showing the calibration steps of the ISE in a MCh solution.

[0132] FIGS. 15A-15C provide exemplary blueprints for the support component of the OPM system. FIG. 15A provides an exemplary blueprint from a top-down view of the support component of the OPM system. FIG. 15B provides an exemplary blueprint from a back view of the support component of the OPM system. FIG. 15C provides an exemplary overview of the support component of the OPM system.DETAILED DESCRIPTION

[0133] The present disclosure discloses methods of characterizing chemical processes or biological processes using a magnetic levitation system. In some aspects, the present application relates to methods for optical and potentiometric characterization of chemical processes or biological processes using a magnetic levitation system. In other aspects, the present application relates to optical and potentiometric characterization of enzyme activity using a magnetic levitation system.

[0134] In accordance with one aspect, the present disclosure describes a magnetic levitation system incorporating one or more sensors. In certain embodiments, a first sensor is a light-intensity sensor. In certain embodiments, the light-intensity sensor measures light absorbed or transmitted through a sample in the magnetic levitation system. In certain embodiments, the light-intensity sensor measures the turbidity of the sample. In certain embodiments, a second sensor is a potentiometric sensor. In certain embodiments, the potentiometric sensor measures an electrochemical potential generated by a sample in the magnetic levitation system.

[0135] In accordance with one aspect, the present disclosure describes a magneticlevitation system incorporating a light source. In certain embodiments, the light source is a laser. In certain embodiments, the laser is a laser pointer. In certain embodiments, the laser is shone through a sample in the magnetic levitation system.

[0136] In accordance with one aspect, the present disclosure provides a method for providing optical and potentiometric characterization of a sample using a magnetic levitation system. In certain embodiments, the sample is a magnetically levitated droplet within a paramagnetic medium, held within the magnetic levitation system. In certain embodiments, the droplet is an emulsion. In certain embodiments, the droplet is turbid, transparent, or transitions from turbid to transparent. In certain embodiments, the change in transparency of the sample is correlated with a biological or chemical process. In certain embodiments, the change in transparency of the sample is correlated with the change in concentration of MCh in the sample. In certain embodiments, the change in transparency of the sample is used to measure the rate of hydrolysis of MCh by BChE. In certain embodiments, the hydrolysis results in generation of myristate ions.

[0137] In accordance with one aspect, the reaction product partitions between the droplet and the paramagnetic medium. In certain embodiments, the reaction product concentration in the paramagnetic medium is measured by an ion-selective electrode (ISE). In certain embodiments, the change in potential measured by the ISE in the paramagnetic medium, is used to measure the rate of hydrolysis of a starting material catalyzed by an enzyme. In certain embodiments, the potential measured by ISE depends on the increase in concentration of reaction product. In certain embodiments, the potential measured by ISE depends on the decrease in concentration of the starting material. In certain embodiments, the potential measured by ISE is contributed by both the concentration of the starting material and the concentration of the reaction product.

[0138] In accordance with one aspect, the method for providing optical and potentiometric characterization of a sample using a magnetic levitation system is described, including: (a) adding a paramagnetic medium to a vessel, (b) inserting the vessel between two magnets within the magnetic levitation system, (c) inserting a first phase to the sample holder, thus creating a magnetically levitated droplet of the first phase within the paramagnetic medium, (d) aligning a light source with the magnetically levitated droplet, (e) positioning a light-intensity sensor on the opposite side of the magnetic levitation system from the light source, and (f) disposing an ion-selective electrode within the paramagnetic medium. In certain embodiments, theparamagnetic medium is an aqueous solution. In certain embodiments, the paramagnetic medium is an aqueous solution of Manganese Chloride tetrahydrate. In certain embodiments, the sample holder is a cuvette. In certain embodiments, the first phase is an emulsion. In certain embodiments, the emulsion is created between an organic solvent and water or an aqueous solution. In certain embodiments, the organic solvent is nitrophenyl octyl ether (NPOE). In certain embodiments, the aqueous solution is an aqueous solution of a choline derivative. In certain embodiments, the choline derivative is myristoylcholine (MCh). In certain embodiments, an additional compound, sample, reagent, or mixture is added to either one or both of the first phase and the paramagnetic medium. In certain embodiments, the additional compound, sample reagent, or mixture includes a solution of butyrylcholinesterase (BChE) or human serum. In certain embodiments, the solution of BChE or human serum includes an additive. In certain embodiments, the additive is an enzyme inhibitor. In certain embodiments, the enzyme inhibitor is paraoxon. In certain embodiments, the light source is a laser. In certain embodiments, the laser is a laser pointer. In certain embodiments, the lightintensity sensor is a light transmittance sensor.

[0139] In accordance with one aspect, a system (10, see FIGS. 1A-B). In certain embodiments, the system includes a first magnet (101) and a second magnet (102). In certain embodiments, the magnets are oriented such that the north pole of the first magnet (101) faces the north pole of the second magnet (102). In certain embodiments, the magnets are oriented such that the south pole of the first magnet (101) faces the south pole of the second magnet (102). In certain embodiments, the first magnet (101) and the second magnet (102) are each independently a permanent magnet or an electromagnet. In certain embodiments, the first magnet (101) and the second magnet (102) are each independently a permanent magnet. In certain embodiments the first magnet (101) and the second magnet (102) are independently composed of NdFeB. In certain embodiments, the first magnet (101) and the second magnet(102) are ring magnets with a sample vessel placed at the center.

[0140] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes a vessel(103). In certain embodiments, the vessel (103) is disposed between the first magnet (101) and the second magnet (102) (FIG. IB). In certain embodiments, the vessel (103) is transparent, semi-transparent, or translucent. In certain embodiments, the vessel (103) is transparent. In certain embodiments, the vessel material is glass, polycarbonate, plastic, or quartz. In certain embodiments, the vessel material is glass, plastic, quartz, polycarbonate,polymethylmethacrylate, or a combination thereof. In certain embodiments, the vessel (103) comprises flat sides. In certain embodiments, the vessel (103) is a cuvette. In certain embodiments, the vessel (103) is a squared-section cuvette.

[0141] In accordance with one aspect, the vessel (103, see FIGS. 1A-B) is configured to receive a first phase (104) and a second phase (105). In certain embodiments, the first magnet (101) and the second magnet (102) are configured to levitate the first phase (104). In certain embodiments, the first phase (104) and the second phase (105) are immiscible. In certain embodiments, the first phase (104) and the second phase (105) are partially miscible. In certain embodiments, a material transfer consisting of particles, ions, neutral molecules, or macromolecules can occur from the first phase (104) to the second phase (105), or from the second phase (105) to the first phase (104). In certain embodiments, the first phase (104) is a liquid, a solid, a solution, a suspension, an emulsion, a colloid, a microemulsion, a liquid crystal, or a gel. In certain embodiments, the first phase (104) is a liquid, a solution, a colloid, or an emulsion. In certain embodiments, the first phase (104) is an emulsion. In certain embodiments the emulsion is composed of an organic solvent and an amphiphile. In certain embodiments, the organic solvent is nitrophenyl octyl ether, octane, octanol, heptane, heptanol, hexane, hexanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, another water- immiscible solvent, or any combination thereof. In certain embodiments, the aqueous solution contains a substrate and an enzyme or a human serum. In certain embodiments, the amphiphile is the substrate used for detecting enzymatic activity. In certain embodiments, the substrate is a choline derivative. In certain embodiments, the substrate is succinyl choline or myristoylcholine. In certain embodiments, the substrate is myristoylcholine. In certain embodiments, the first phase (104) is turbid or transparent or transitions from being transparent to being turbid. In certain embodiments, the first phase (104) transitions from being turbid to being transparent. In certain embodiments, the second phase is a paramagnetic medium. In certain embodiments, the second phase (105) is a paramagnetic medium comprising an aqueous solution of paramagnetic salts or an aqueous-organic hybrid solution of paramagnetic salts. In certain embodiments, the second phase (105) is a paramagnetic medium comprising an aqueous solution of paramagnetic salts. In certain embodiments, the paramagnetic salts are one or more of MnCh, MnBr2, FeCh, FeCh, CoBrc, GdCh, Gd2(SO4)s, Er2(SO4)s, and CuSCh. In certain embodiments, the aqueous solution is a solution of MnCh. In certain embodiments, the aqueous solution contains a sample. In certain embodiments, the sample contains one or more of an enzyme or a human serum. In certain embodiments, the enzyme is butyrylcholinesterase.

[0142] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes a light source (106), the light source configured to transmit an optical radiation through the first phase (104). In certain embodiments, the light source (106) transmits ultraviolet, visible, or infrared radiation. In certain embodiments, the light source (106) transmits visible radiation. In certain embodiments, the light source (106) transmits visible radiation at a wavelength of 660 nm. In certain embodiments, the light source (106) is a laser, a lamp, or a light emitting diode. In certain embodiments, the light source (106) is a laser. In certain embodiments, the light source(106) is a laser pointer. In certain embodiments the light source (106) is aligned with the first phase (104).

[0143] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes a first sensor (107), the first sensor configured to measure a transmittance of an optical radiation from or through the first phase (104). In certain embodiments, the first sensor (107) is a light sensor. In certain embodiments, the first sensor (107) is a photodetector. In certain embodiments, the first sensor (107) is a photodetector for an ultraviolet-visible spectrophotometer. In certain embodiments, the first sensor (107) is aligned with the first phase (104). In certain embodiments, the first sensor (107) is configured to measure light emitted from the first phase (104) or light transmitted through the first phase (104). In certain embodiments, the first sensor(107) is a photodetector for an ultraviolet-visible spectrophotometer; the photodetector being aligned with the first phase (104); and the photodetector being configured to measure light transmitted through the first phase (104).

[0144] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes a second sensor (108), the second sensor configured to measure an electrochemical potential that reflects the concentration of an ionic reagent or ionic product in the second phase (105). In certain embodiments, the second sensor (108) is one or more ion selective electrodes. In certain embodiments, the second sensor (108) is one ion selective electrode. In certain embodiments, the ion selective electrode includes an ion selective membrane. In certain embodiments, the second sensor (108) is selective for a given reagent or product. In certain embodiments, the second sensor (108) is an ion selective electrode configured to measure an electrochemical potential generated between the ion selective membrane and the second phase (105) on the basis of the concentration of a given reagent or product in the second phase. In certain embodiments, the potential measured by the ion selective electrode reflects the concentration of ions in the second phase (105) because the potential is generated at the ISE membranesurface in contact with the second phase (105) and measured across the electrochemical junction. In certain embodiments, the ion selective membrane is selective for myristoyl choline.

[0145] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes an optical filter (109). In certain embodiments, the optical filter (109) is a neutral density filter. In certain embodiments, the optical filter (109) is positioned between the light source (106) and the vessel(103).

[0146] In accordance with one aspect, the system (10, see FIGS. 1A-B) includes a first magnet (101) and a second magnet (102); a vessel (103) held between the first magnet and the second magnet, the vessel configured to receive a first phase (104) and a second phase (105), the first magnet (101) and second magnet (102) configured to levitate the first phase; a light source (106) the light source configured to transmit an optical radiation through the first phase(104); a first sensor (107), the first sensor configured to measure a transmittance of an optical radiation from or through the first phase (104); a second sensor (108), the second sensor configured to measure an electrical potential generated at the interface between the ion selective membrane and the second phase; and an optical filter (109) positioned between the light source (106) and the vessel (103).

[0147] In accordance with one aspect, the present disclosure provides a method comprising: providing a first phase and a second phase either separately or together to a vessel; disposing the vessel between a first magnet and a second magnet, the disposal of the vessel between the first magnet and the second magnet causing the first phase to levitate; transmitting an optical radiation through the first phase using a light source; measuring a transmittance of optical radiation from or through the first phase using a first sensor; and measuring an electrochemical potential in the second phase using a second sensor.

[0148] In accordance with one aspect, the method involves providing the first phase and the second phase separately to the vessel. In certain embodiments, the second phase is provided to the vessel before providing the first phase to the vessel. In certain embodiments, the second phase is provided to the vessel, then the vessel is disposed between the first magnet and the second magnet before providing the first phase to the vessel. In certain embodiments, the second phase is provided to the vessel, then the vessel is disposed between the first magnet and the second magnet, then the first phase is added to the vessel where it is magnetically levitatedby the first magnet and the second magnet. In certain embodiments, an additional compound, reagent, or mixture is added to either one of or both of the first phase and the second phase. In certain embodiments an additional mixture comprising an aqueous solution of butyrylcholinesterase or human serum is added to the second phase.1. MCh, SuCh and BChE

[0149] To explore possible applications of the system for optical characterization of chemical or biological processes, experiments were designed to analyze the enzyme kinetics of the hydrolysis of myristoyl choline (MCh) performed by BChE using the magnetic levitation system coupled with optical detection and ion selective sensing. MCh was chosen to serve as an analogue for succinylcholine (SuCh) which is a muscle relaxant or anesthetic used in medical procedures. FIGS. 1A-B provide the chemical structures of MCh and SuCh. To examine the MCh hydrolysis kinetics, an enzyme responsive active emulsion system was stabilized with myristoyl choline (MCh)(10), a cationic surfactant presenting an amphiphilic structure (11, 12). In FIG. IB it can be seen that the molecular structure of MCh has two components: a polar head N(CH3)3, and a 14-carbon nonpolar tail, connected by an ester bond that cholinesterases such as BChE can cleave through enzymatic hydrolysis.2. Optical-Potentiometric-Magnetic levitation System

[0150] FIGS. 2 and 3 illustrate an exemplary optical-potentiometric-magnetic levitation (0PM) system coupled with a light source and a light sensor. FIGS. 4-8 illustrate the components of the 0PM system. In some aspects of the present disclosure, the 0PM system integrates five components comprising a magnetic levitation apparatus (FIG. 4), a light source, a light sensor, a neutral density filter (FIG. 5), and an ion-selective electrode (ISE) (FIG 6). In certain embodiments, the magnetic levitation apparatus is used to levitate droplets. In certain embodiments, the light source is a laser. In certain embodiments, the laser is a laser pointer (FIG. 7). In certain embodiments, the light sensor is a photodetector. In certain embodiments, the light sensor is a photodetector for a UV-Visible spectrophotometer (FIG. 8). In certain embodiments, the UV-Visible spectrophotometer is used to measure discrete or visible wavelengths of light. In certain embodiments, the ISE converts the change in the concentration of a specific ion dissolved in a solution into an electrical potential. In certain embodiments, the system is coupled with an ISE to track the hydrolysis rate of an amphiphile at the aqueous- organic interface of an active emulsion system. In certain embodiments the ISE monitors theconcentration of the amphiphile of an active emulsion system.

[0151] In accordance with one aspect, the OPM system is used to analyze enzyme kinetics. In certain embodiments, the OPM system is used to analyze reaction kinetics of the hydrolysis of MCh catalyzed by BChE. Analysis of enzyme activity using the OPM system presents possible applications of the OPM system in the biomedical field. For example, analysis of enzyme kinetics is useful for identifying poor metabolizers, diagnosing people who have been exposed to pesticides, and testing recombinant enzymes (e.g. BChE) which are commercially produced. When an emulsified mixture containing NPOE, MCh, and water is loaded into the MagLev system, an ensemble of many smaller emulsion droplets is levitated in a paramagnetic manganese chloride solution held within the sample holder. The addition of a BChE solution causes hydrolysis of MCh, leading to a collective behavior of active emulsion droplets (Herminghaus, S. et al. 2014, Soft Matter, 10, 36, 7008-7022). As FIG. 9 illustrates, emulsions with equal ratios of water-to-organic concentration but different droplet diameters have different light transmittance spectra. The largest emulsion droplets are characterized by a higher relative clarity, whereas smaller emulsion droplets scatter light more, leading to a lower relative clarity, especially at higher wavelengths, due to an increase in light scattering. As shown in FIG. 9, different-sized emulsions (created by vortex mixing over different durations) present a different light transmittance throughout all the wavelengths.

[0152] To account quantitatively for the hydrolysis of MCh, the OPM system was used, and two identical emulsion mixtures were individually characterized using two different concentrations of BChE. As the hydrolysis of MCh progressed, the aggregation progressed from a turbid ellipse to a spherical, transparent droplet surrounded by white clouds of the insoluble reaction product, myristic acid (FIG. 10). Transparent droplets formed with a rate proportional to the concentration of BChE and fused within the solution aggregate, deforming the ellipse and causing a decrease in the droplet’s turbidity and an increase in its light transmittance (FIG. 10B)

[0153] For the OPM system, a laser was shone through the droplet into an optical detector, to quantify the change of the emulsion’s opacity over time. As described in the EXPERIMENTAL METHOD, two emulsion mixtures of NPOE in water were created. To one of the NPOE emulsion mixture, 0.1 ml of a 50 U / mL stock solution of BChE was added. To the other emulsion, 0.05 ml of the same BChE stock solution was added. FIG. 11 (top plot) shows that the change in light intensity over time for the sample with 0.1 mL of BChE (bluecurve) is characterized by a significantly steeper slope, which is correlated to a higher hydrolysis rate. Therefore, this represents an elevated active BChE concentration when compared with the sample to which 0.05 mL BChE was added (red curve). As FIG. 11 (bottom plot) illustrates, the initial starting point of the light intensity does not affect the rate of increase of the light intensity, as the slope of the curve relates to the activity of BChE.3. OPM system on Human serum

[0154] To further test the OPM system for biomedical applications, the same procedure described above was repeated with the addition of human serum instead of adding a BChE stock solution. Two emulsion mixtures were prepared. A different amount of chemically identical human serum (0.05 mL and 0.025 mL, respectively) was added to each magnetically levitated emulsion mixture. A third emulsion mixture was created and 0.025 mL of BChE stock solution that had been deactivated with paraoxon was added as a control to confirm that the data collected were related to BChE’s activity and not to other active enzymes present in plasma. The results of these experiments are shown in FIG. 12. Since the paraoxon is a specific inhibitor for BChE and Acetylcholinesterase (AChE), the inactivity of the inhibited sample suggests that the results collected are mainly related to the BChE’s function. Results show that there is a strong correlation between the slope of the curve and BChE’s activity in samples measured.

[0155] A statistical analysis has been run on the previously presented data, all presenting a T value below 0.05, therefore proving the technique’s statistical significance.4. Ion Selective Electrode Sensing

[0156] The optical results from the experiments with the OPM system were compared with the concurrent hydrolysis curves from ISE measurements of the paramagnetic solution surrounding the active emulsion droplets in each OPM experiment described above. In order to integrate the MCh-selective electrode into the MagLev system, a thread-based ion-selective electrode, selective for MCh ions, was used and a calibration curve with similar slope and linear (dynamic) range was obtained under the same experimental conditions compared to that of a conventionally assembled ISE system (~105- l 02M). This observation indicates that the thread-based MCh electrode functions as well as the classical liquid contact ISEs used in conventional potentiometric measurements and can be used reliably in monitoring the BChE- catalyzed MCh hydrolysis.

[0157] The decrease in the concentration of MCh ions measured by the ISE results from hydrolysis of MCh by BChE. The same amounts of MCh solution and concentrations of BChE solution were used in experiments integrating the ISE as were used in experiments with the 0PM system alone. As shown by the 0PM system, the ISE experiments also illustrated that the rate of MCh hydrolysis by BChE is strictly correlated to the concentration of BChE. The results are shown in FIG. 13.

[0158] A comparison of the data shown in FIGS. 11 and 13 illustrates how the ISE curves and the curves from the 0PM system are highly correlated. A correspondence can be seen between the slope of the curve describing the increase in intensity of light over time and the one describing the decrease of the concentration of MCh ions in solution. The correlation between the two graphs confirms the validity of the optical characterization method using the 0PM system.

[0159] In conclusion, using the 0PM system and enzyme reactive active emulsion systems to analyze the difference in BChE activity in human samples was achieved. The 0PM system enables the tracking of enzyme activity by analyzing the intensity of light transmitted through the emulsion droplets. The utilization of the 0PM system can yield numerous advantages across various fields, varying from research to biomedical analysis. Its further development and implementation hold promising potential as a valuable technique in biomedicine. The present study on human serum can in future studies be standardized to be used as an affordable and effective way to determine a patient's BChE activity.EXPERIMENTAL METHOD

[0160] To a squared-section transparent cuvette, 4mL of 0.75M Manganese Chloride aqueous solution was added. The cuvette was then inserted inside of the magnetic levitation system. To a separate preparation vial, 1 mL of a lOmM Myristoylcholine (MCh) aqueous solution and 0.1 mL of nitrophenyl octyl ether (NPOE) was added. This ImL mixture was then emulsified through the use of a vortex mixer for 10 seconds. 0.1 mL of this emulsified mixture was then added to the cuvette inside of the MagLev system. A 660 nm wavelength laser was aligned with the drop and a light transmittance sensor was positioned on the opposite side. Upon stabilization of emulsion droplets inside of the Maglev, 0.1 mL of a 50 U / ml solution of BChE was added to the mixture. As soon as the droplet returned to its oval shape, the 0PM system was utilized in a dark and controlled environment. The same procedure was then reneated with different amount of enzymes, by individually adding 0.08, 0.065 or 0.05 ml ofthe 50 U / ml stock solution of BChE. As a control, the same experiment was also repeated with the addition of 0.05 ml of BChE stock that was previously deactivated by paroxon (8). Subsequently, the same experiment was run substituting 50 U / mL solution of BChE with different quantities of human serum. The human serum is characterized by an average concentration of BChE of 3 U / ml. 0.05 and 0.025 ml of serum were added to the levitated emulsion systems as two different samples. A control was executed by repeating the procedure with 0.025 mL of inhibited BChE. To correlate ISE readings with the concentration of the substrate, a 5 mM solution (followed by a series of 2-fold dilution) of the substrate was prepared separately and electrochemical potentials were measured using an ion selective electrode vs. a Ag / AgCl reference electrode, as shown in FIG. 14. To validate the method of using ISE for measuring the rate of hydrolysis, three volumes of the 50U / mL BChE solution (0.1, 0.08 and 0.065 ml) were separately added to three MCh solutions (0.25mM, below its CMC (9)) with stirring.1. Optical-Potentiometric-Magnetic levitation System

[0161] FIGS. 15A-C provide exemplary blueprints for the support component of the 0PM system. All the measurements needed for the replication of the support are listed on the blueprints, in millimeters (mm). It is valid to note that perfect fit is not necessary, yet the tighter the fit the higher are the chances for a proper experiment. Furthermore, alignment should be considered because changing it might alter results during the process, considering the trajectory of the light beam being shot.REFERENCES1. Ashkarran, A. A.; Suslick, K. S.; Mahmoudi, M. Magnetically Levitated PlasmaProteins. Analytical Chemistry 2020, 92 (2), 1663-1668. https: / / doi.org / 10.1021 / acs.analchem.9b05101.2. Ge, S.; Nemiroski, A.; Mirica, K. A.; Mace, C. R.; Hennek, J. W.; Kumar, A. A.; Whitesides, G. M. Magnetic Levitation in Chemistry, Materials Science, and Biochemistry. Angewandte Chemie International Edition 2020, 59 (41), 17810-17855.3. (2)Mirica, K. A.; Phillips, S. T.; Shevkoplyas, S. S.; Whitesides, G. M. Using Magnetic Levitation to Distinguish Atomic-Level Differences in Chemical Composition of Polymers, and to Monitor Chemical Reactions on Solid Supports. Journal of theAmerican Chemical Society 2008, 130 (52), 17678-17680. https: / / doi.org / 10.1021 / ja8074727. Darvesh, S.; Hopkins, D. A.; Geula, C. Neurobiology of Butyrylcholinesterase. Nature Reviews Neuroscience 2003, 4 (2), 131-138. https: / / doi.org / 10.1038 / nml035. 3 Butyrylcholine - an overview \ ScienceDirect Topics, www.sciencedirect.com. Gulenay, M.; Mathai, J. K. Depolarizing Neuromuscular Blocking Drugs. PubMed. https: / / www.ncbi.nlm.nih.gOv / books / NBK532996 / #:~:t What is precision medicine?: MedlinePlus Genetics https: / / medlineplus.gov / genetics / understanding / precisionmedicine / defmition / (accessed 2021 -07 -11). Amitai, G.; Moorad, D.; Adani, R.; Doctor, B. P. Inhibition of Acetylcholinesterase and Butyrylcholinesterase by Chlorpyrifos-Oxon. Biochem. Pharmacol. 1998, 56 (3), 293- 299. https: / / d0i.0rg / l 0.1016 / s0006-2952(98)00035-5. Hoffmann, H.; Ebert, G. Surfactants, Micelles and Fascinating Phenomena. Angew. Chem. Int. Ed. Engl. 1988, 27 (7), 902-912. https: / / doi.org / 10.1002 / anie.198809 Pub Chem. Myristoyl Choline chloride. Pub Chem. https: / / pubchem.ncbi.nlm.nih.gov / compound / Myristoylcholine-chloride. Amphiphilic Molecule - an overview \ ScienceDirect Topics, www.sciencedirect.com. https: / / www.sciencedirect.com / topics / engineering / amphiphilic-molecule. SimScience - Amphiphiles as surfactants (red level), sethna.lassp.comell.edu. https: / / sethna.lassp.cornell.edu / SimScience / membranes / advanced / essay / surfactants.ht ml. Herminghaus, S.; Maass, C. C.; Kruger, C.; Thutupalli, S.; Goehring, L.; Bahr, C. Interfacial Mechanisms in Active Emulsions. Soft Matter 2014, 10 (36), 7008-7022. https: / / doi.org / 10.1039 / c4sm00550c.

Claims

CLAIMSWhat is clamed is:

1. A system comprising: a first magnet and a second magnet, a vessel held between the first magnet and the second magnet, the vessel configured to receive a first phase and a second phase, the first magnet and the second magnet configured to levitate the first phase; a light source configured to transmit an optical radiation through the first phase; a first sensor configured to measure a transmittance of an optical radiation from or through the first phase; and a second sensor configured to measure an electrochemical potential in the second phase.

2. The system of claim 1, wherein the north pole of the first magnet faces the north pole of the second magnet.

3. The system of claim 1, wherein the south pole of the first magnet faces the south pole of the second magnet.

4. The system of any one of claims 1 to 3, wherein the first magnet and the second magnet each independently comprise a permanent magnet or an electromagnet.

5. The system of any one of claims 1 to 4, wherein the first magnet and the second magnet each independently comprise a permanent magnet.

6. The system of any one of claims 1 to 3, or 5, wherein the first magnet and the second magnet each independently comprise one or more of Nd, NdFeB, SmCo, ceramic, or AlNiCo.

7. The system of any one of claims 1 to 3, or 5 to 6, wherein the first magnet and the second magnet each independently comprise NdFeB.

8. The system of any one of claims 1 to 7, wherein the vessel is one of transparent, semitransparent, or translucent.

9. The system of any one of claims 1 to 8, wherein the vessel is transparent.

10. The system of any one of claims 1 to 9, wherein the vessel comprises flat sides.

11. The system of any one of claims 1 to 10, wherein the vessel is a squared- section cuvette.

12. The system of any one of claims 1 to 11, wherein the vessel material comprises one or more of glass, plastic, quartz, polycarbonate, polymethylmethacrylate.

13. The system of any one of claims 1 to 12, wherein the first phase and the second phase are immiscible.

14. The system of any one of claims 1 to 12, wherein the first phase and the second phase are partially miscible.

15. The system of any one of claims 1 to 14, wherein, at the interface between the first phase and the second phase, a transfer of one or more of an ion, a molecule, an amphiphile, a chemical reagent, a biomolecule, or a macromolecule occurs from the first phase to the second phase or the second phase to the first phase.

16. The system of any one of claims 1 to 15, wherein the first phase comprises one or more of a liquid, a solid, a solution, a suspension, an emulsion, a colloid, a microemulsion, a liquid crystal, or a gel.

17. The system of any one of claims 1 to 16, wherein the first phase comprises one or more of a liquid, a solution, an emulsion, or a colloid.

18. The system of any one of claims 1 to 17, wherein the first phase comprises an emulsion.

19. The system of any one of claims 18, wherein the emulsion comprises a first aqueous solution and an organic solvent, wherein the first aqueous solution comprises an amphiphile.

20. The system of claim 19, wherein the amphiphile comprises myristoylcholine.

21. The system of either one of claims 19 or 20, wherein the organic solvent comprises one or more of nitrophenyl octyl ether, hexane, hexanol, heptane, heptanol, octane, octanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, or another water-immiscible solvent.

22. The system of any one of claims 19 to 21, wherein the organic solvent comprises nitrophenyl octyl ether.

23. The system of any one of claims 1 to 22, wherein the first phase is turbid, or transparent, transitions from being turbid to being transparent, or transitions from being transparent to being turbid.

24. The system of any one of claims 1 to 23, wherein the second phase comprises a paramagnetic medium.

25. The system of any one of claims 24, wherein the paramagnetic medium comprises a second aqueous solution, wherein the second aqueous solution comprises paramagnetic salts; or an aqueous-organic hybrid solution of paramagnetic salts.

26. The system of claim 25, wherein the second aqueous solution comprises one or more of MnCh, MnBr2, FeCh, FeCh, CoBr2, GdCh, Gd2(SO4)3, Er2(SO4)3, and CuSO4.

27. The system of claim 25, wherein the aqueous-organic hybrid solution comprises one or more of a water-methanol mixture, a water-ethanol mixture, a water-propanol mixture, a water-acetonitrile mixture, a water-dimethyl sulfoxide mixture.

28. The system of any one of claims 25 to 27, wherein the second aqueous solution comprises MnCh.

29. The system of any one of claims 25 to 28, wherein the second aqueous solution comprises a substrate and an enzyme.

30. The system of claim 29, wherein the substrate comprises a choline derivative, and the enzyme comprises butyrylcholine esterase.

31. The system of either one of claims 29 or 30, wherein the substrate comprises one or more of succinyl choline or myristoylcholine.

32. The system of any one of claims 29 to 31, wherein the substrate comprises myristoylcholine.

33. The system of any one of claims 25 to 32, wherein the second aqueous solution comprises human serum.

34. The system of any one of claims 1 to 33, wherein the light source transmits one or more of ultraviolet, visible, infrared radiation.

35. The system of any one of claims 1 to 34, wherein the light source transmits visible radiation at a wavelength of 660 nm.

36. The system of any one of claims 1 to 35, wherein the light source comprises a laser, a lamp, a light emitting diode, or a combination thereof.

37. The system of any one of claims 1 to 36, wherein the light source comprises a laser pointer.

38. The system of any one of claims 1 to 37, wherein the first sensor comprises a light sensor.

39. The system of any one of claims 1 to 38, wherein the first sensor comprises a photodetector.

40. The system of claim 39, wherein the photodetector comprises a photodetector for a ultraviolet-visible spectrophotometer.

41. The system of any one of claims 1 to 40, wherein the first sensor is aligned with the first phase.

42. The system of any one of claims 1 to 41, wherein the first sensor is configured to measure one or more of light emitted from the first phase, or light transmitted through the first phase.

43. The system of any one of claims 1 to 42, wherein the first sensor comprises a photodetector for an ultraviolet-visible spectrophotometer; the photodetector being aligned with the first phase; and the photodetector being configured to measure light transmitted through the first phase.

44. The system of any one of claims 1 to 43, wherein the second sensor comprises one or more ion-selective electrodes.

45. The system of any one of claims 1 to 44, wherein the ion selective electrode is selective for ions in the second phase.

46. The system of any one of claims 1 to 45, wherein the ion selective electrode is selective for succinylcholine ions or myristoylcholine ions.

47. The system of any one of claims 1 to 46, wherein the second sensor is an ion-selective electrode configured to measure an electrochemical potential in the second phase based on a concentration of the myristoylcholine ions in the second phase.

48. The system of any one of claims 1 to 47, comprising an optical filter.

49. The system of claim 48, wherein the optical filter comprises a neutral density filter positioned between the light source and the vessel.

50. The system of any one of claims 1 to 49, the system comprising: a first magnet and a second magnet, a vessel held between the first magnet and the second magnet, the vessel configured to receive a first phase and a second phase, the first magnet and the second magnet configured to levitate the first phase; a light source, the light source configured to transmit an optical radiation through the first phase; a first sensor, the first sensor configured to measure a transmittance of an optical radiation from or through the first phase; anda second sensor, the second sensor configured to measure an electrochemical potential in contact with the second phase; wherein: the first magnet and the second magnet comprise NdFeB; the vessel is a transparent, squared-section cuvette, and the vessel material comprises quartz; the first phase is an emulsion comprising nitrophenyl octyl ether and a first aqueous solution, wherein the first aqueous solution comprises an amphiphile, wherein the amphiphile is myristoylcholine; the second phase is a paramagnetic medium comprising a second aqueous solution, wherein the second aqueous solution comprises MnCh, and one of butyrylcholinesterase or human serum; the light source comprises a laser pointer configured to transmit 660 nm optical radiation through the first phase; the first sensor comprises a photodetector for an ultraviolet-visible spectrophotometer configured to measure light transmitted from the light source through the first phase; the second sensor comprises an ion-selective electrode configured to measure an electrochemical potential in the second phase on the basis of the concentration of myristoylcholine ions in the second phase; and wherein the system comprises a neutral density filter positioned between the light source and the vessel.

51. A method compri sing : providing a first phase and a second phase either separately or together to a vessel; disposing the vessel between a first magnet and a second magnet, the disposal of the vessel between the first magnet and the second magnet causing the first phase to levitate; transmitting an optical radiation through the first phase using a light source; measuring a transmittance of optical radiation from or through the first phase using a first sensor; and measuring an electrochemical potential in the second phase using a second sensor.

52. The method of claim 51, wherein the second phase is provided to the vessel before or after providing the first phase to the vessel.

53. The method of either one of claims 51 or 52, wherein the vessel is disposed between the first magnet and the second magnet before or after providing the first phase to the vessel.

54. The method of any one of claims 51 to 53, wherein the second phase is provided to the vessel, the vessel is disposed between the first magnet and the second magnet, and then the first phase is provided to the vessel.

55. The method of any one of claims 51 to 54, further comprising providing one or more additional compounds, reagents, or mixtures to either one of or both of the first phase and the second phase.

56. The method of claim 55 further comprising providing a mixture of water and either one of butyrylcholine esterase, or human serum to the second phase.

57. The method of any one of claims 51 to 56, wherein the north pole of the first magnet faces the north pole of the second magnet.

58. The method of any one of claims 51 to 57, wherein the south pole of the first magnet faces the south pole of the second magnet.

59. The method of any one of claims 51 to 58, wherein the first magnet and the second magnet each independently comprise a permanent magnet or an electromagnet.

60. The method of any one of claims 51 to 59, wherein the first magnet and the second magnet each independently comprise a permanent magnet.

61. The method of any one of claims 51 to 58, or 60, wherein the first magnet and the second magnet each independently comprise one or more of Nd, NdFeB, SmCo, ceramic, or AlNiCo.

62. The method of any one of claims 51 to 58, or 60 to 61, wherein the first magnet and the second magnet each independently comprise NdFeB.

63. The method of any one of claims 51 to 62, wherein the vessel is one of transparent, semi-transparent, or translucent.

64. The method of any one of claims 51 to 63, wherein the vessel is transparent.

65. The method of any one of claims 51 to 64, wherein the vessel comprises flat sides.

66. The method of any one of claims 51 to 65, wherein the vessel is a squared-section cuvette.

67. The method of any one of claims 51 to 66, wherein the vessel material comprises one or more of glass, plastic, quartz, polycarbonate, polymethylmethacrylate.

68. The method of any one of claims 51 to 67, wherein the first phase and the second phase are immiscible.

69. The method of any one of claims 51 to 68, wherein the first phase and the second phase are partially miscible.

70. The method of any one of claims 51 to 69, wherein, at the interface between the first phase and the second phase, a transfer of one or more of an ion, a molecule, an amphiphile, a chemical reagent, a biomolecule, or a macromolecule occurs from the first phase to the second phase or the second phase to the first phase.

71. The method of any one of claims 51 to 70, wherein the first phase comprises a liquid, a solid, a solution, a suspension, an emulsion, a colloid, a microemulsion, a liquid crystal, or a gel, or a combination thereof.

72. The method of any one of claims 51 to 71, wherein the first phase comprises a liquid, a solution, an emulsion, a colloid, or a combination thereof.

73. The method of any one of claims 51 to 72, wherein the first phase comprises an emulsion.

74. The method of claim 73, wherein the emulsion comprises a first aqueous solution and an organic solvent, wherein the first aqueous solution comprises an amphiphile.

75. The method of claim 74, wherein the amphiphile is myristoylcholine.

76. The method of either one of claims 74 or 75, wherein the organic solvent comprises one or more of nitrophenyl octyl ether, hexane, hexanol, heptane, heptanol, octane, octanol, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, or another water-immiscible solvent.

77. The method of any one of claims 74 to 76, wherein the organic solvent comprises nitrophenyl octyl ether.

78. The method of any one of claims 51 to 77, wherein the first phase is turbid, or transparent, transitions from being turbid to being transparent, or transitions from being transparent to being turbid.

79. The method of any one of claims 51 to 78, wherein the second phase comprises a paramagnetic medium.

80. The method of any one of claims 79, wherein the paramagnetic medium comprises a second aqueous solution, wherein the second aqueous solution comprises paramagnetic salts; or an aqueous-organic hybrid solution of paramagnetic salts.

81. The method of claim 80, wherein the paramagnetic salt comprises one or more of MnCh, MnBr2, FeCh, FeCl3, CoBr2, GdCl3, Gd2(SO4)3, Er2(SO4)3, and CuSO4.

82. The method of claim 80, wherein the aqueous-organic hybrid solution comprises one or more of a water-methanol mixture, a water-ethanol mixture, a water-propanol mixture, a water-acetonitrile mixture, or a water-dimethylsulfoxide.

83. The method of any one of claims 80 to 82, wherein the second aqueous solution comprises MnCh.

84. The method of any one of claims 80 or 83, wherein the second aqueous solution comprises a substrate and an enzyme.

85. The method of claim 84, wherein the substrate comprises a choline derivative, and the enzyme comprises butyrylcholine esterase.

86. The method of either one of claims 84 or 85, wherein the substrate comprises one or more of succinyl choline or myristoylcholine.

87. The method of any one of claims 84 to 86, wherein the substrate comprises myristoylcholine.

88. The method of any one of claims 51 to 87, wherein the second aqueous solution comprises human serum.

89. The method of any one of claims 51 to 88, wherein the light source transmits one or more of ultraviolet, visible, or infrared radiation.

90. The method of any one of claims 51 to 89, wherein the light source transmits visible radiation at a wavelength of 660 nm.

91. The method of any one of claims 51 to 90, wherein the light source comprises one or more of a laser, a lamp, a light emitting diode.

92. The method of any one of claims 51 to 91, wherein the light source comprises a laser pointer.

93. The method of any one of claims 51 to 92, wherein the first sensor comprises a light sensor.

94. The method of any one of claims 51 to 93, wherein the first sensor comprises a photodetector.

95. The method of claim 94, wherein the photodetector comprises a photodetector for an ultraviolet-visible spectrophotometer.

96. The method of any one of claims 51 to 95, wherein the first sensor is aligned with the first phase.

97. The method of any one of claims 51 to 96, wherein the first sensor is configured to measure light emitted from the first phase, light transmitted through the first phase, or a combination thereof.

98. The method of any one of claims 51 to 97, wherein the first sensor comprises a photodetector for an ultraviolet-visible spectrophotometer; the photodetector being aligned with the first phase; and the photodetector being configured to measure light transmitted through the first phase.

99. The method of any one of claims 51 to 98, wherein the second sensor comprises one or more ion-selective electrodes.

100. The method of any one of claims 51 to 99, wherein the ion selective electrode is selective for ions in the second phase.

101. The method of any one of claims 51 to 100, wherein the ion selective electrode is selective for succinylcholine ions or myristoylcholine ions.

102. The method of any one of claims 51 to 101, wherein the second sensor is an ion- selective electrode configured to measure an electrochemical potential in the second phase based on a concentration of myristoylcholine ions in the second phase.

103. The method of any one of claims 51 to 102, the method further comprising providing an optical filter.

104. The method of claim 103, wherein the optical filter comprises a neutral density filter.

105. The method of claim 104, wherein the neutral density filter is positioned between the light source and the vessel.

106. The method of any one of claims 51 to 105, the method comprising: providing a first phase and a second phase to a vessel; disposing the vessel between a first magnet and a second magnet, the disposal of the vessel between the first magnet and the second magnet causing the first phase to levitate; transmitting an optical radiation through the first phase using a light source; measuring a transmittance of optical radiation from or through the first phase using a first sensor; and measuring an electrochemical potential in the second phase using a second sensor, wherein: the first magnet and the second magnet comprise NdFeB; the vessel is a transparent, squared-section cuvette, and the vessel material comprises quartz;the first phase is an emulsion comprising nitrophenyl octyl ether and a first aqueous solution, wherein the first aqueous solution comprises an amphiphile, wherein the amphiphile comprises myristoylcholine; the second phase is a paramagnetic medium comprising a second aqueous solution, wherein the second aqueous solution comprises MnCh, and optionally one or more of butyrylcholinesterase or human serum; the second phase is provided to the vessel, the vessel is disposed between the first magnet and the second magnet, the first phase is provided to the vessel, and a mixture of water and one or more of butyrylcholinesterase or human serum is provided to the second phase; the light source comprises a laser pointer configured to transmit 660 nm optical radiation through the first phase; the first sensor comprises a photodetector for an ultraviolet-visible spectrophotometer configured to measure light transmitted from the light source through the first phase; the second sensor comprises an ion-selective electrode configured to measure an electrochemical potential in the second phase on the basis of the concentration of myristate ions in the second phase; and wherein a neutral density filter is positioned between the light source and the vessel.

Citation Information

Patent Citations

  • Manipulation of magnetic or magnetizable objects using combined magnetophoresis and dielectrophoresis

    US20130043132A1

  • Dual range cardiac troponin immunoassay devices and methods using immunosensor and magnetic immunosensor

    US20180164306A1

  • System and method for cell levitation and monitoring

    US20210373037A1

  • Particle concentrator device and methods of use

    US20220161260A1